Investigational Drug Details
Drug ID: | D342 |
Drug Name: | Solithromycin |
Synonyms: | Solithromycin |
Type: | Chemical drug |
DrugBank ID: | DB09308 |
DrugBank Description: | Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections. |
PubChem ID: | 25242512 |
CasNo: | 760981-83-7 |
Repositioning for NAFLD: | No |
SMILES: | F[C@]1(C(=O)[C@@H]([C@@H](O[C@@H]2O[C@@H](C[C@H](N(C)C)[C@H]2O)C)[C@](OC)(C[C@H](C(=O)[C@@H]([C@H]2N(C(=O)O[C@@]2([C@H](OC1=O)CC)C)CCCCn1nnc(c1)c1cc(N)ccc1)C)C)C)C)C |
Structure: |
|
InChiKey: | IXXFZUPTQVDPPK-ZAWHAJPISA-N |
Molecular Weight: | 845.023 |
DrugBank Targets: | -- |
DrugBank MoA: | -- |
DrugBank Pharmacology: | -- |
DrugBank Indication: | Investigated for the treatment of community-acquired pneumonia (CAP). |
Targets: | NF-kB inhibitor |
Therapeutic Category: | Antibiotic drug, anti-inflammatory |
Clinical Trial Progress: | Phase 2 completed (NCT02510599) |
Latest Progress: | Under clinical trials |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
---|---|---|---|---|---|---|---|
L0197 | NCT02510599 | Phase 2 | Completed | No Results Available | December 2015 | March 21, 2017 | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Article ID | PMID | Source | Title | |
---|---|---|---|---|
A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | Details |
A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | Details |
A17857 | 27521506 | Clin Gastroenterol Hepatol | New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. | Details |